Fortress Biotech, Inc. Business Combination, Contingent Consideration, Liability
Fortress Biotech, Inc. (FBIO) had Business Combination, Contingent Consideration, Liability of $180.00 million as of 2018-11-12, per its 10-Q filed 2020-11-09.
Discontinued › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2020-11-09
- 2018-11-12: Business Combination, Contingent Consideration, Liability $180.00M.
| Period end | Business Combination, Contingent Consideration, Liability |
|---|---|
| 2018-11-12 | $180.00M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |